Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 December 2012Website:
http://www.actiniumpharma.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 22:44:01 GMTDividend
Analysts recommendations
Institutional Ownership
ATNM Latest News
Here is how Actinium Pharmaceuticals (ATNM) and Encompass Health (EHC) have performed compared to their sector so far this year.
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the companies developing innovative solutions, featuring Actinium Pharmaceuticals, Inc. (NYSE American: ATNM).
- Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors - Combination with leading menin inhibitor demonstrates acute myeloid leukemia cell death and significant tumor elimination not achieved with monotherapy - Menin combination expands backbone potential of Actimab-A in acute myeloid leukemia that already includes chemotherapy, venetoclax and FLT3 inhibitors NEW YORK , June 17, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that an abstract detailing the first ever preclinical data from the combination of menin inhibitors with Actinium's ARC Actimab-A in acute myeloid leukemia (AML) models was presented at the 2024 European Hematology Association (EHA) Congress held June 13 – 16, 2024, in Madrid, Spain. Actinium studied Actimab-A in combination with the leading menin inhibitors, revumenib (Syndax Pharmaceuticals, Inc.) and ziftomenib (Kura Oncology, Inc.), which are being developed for patients with KMT2A rearrangements and NMP1 mutations, which are present in approximately 10% and 30% of AML patients, respectively.
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial - Long-term efficacy results in patients with active relapsed or refractory acute myeloid leukemia also observed in the SIERRA trial NEW YORK , June 14, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented at the 2024 European Hematology Association (EHA) Hybrid Congress being held June 13 – 16, 2024, in Madrid, Spain. The two presentations at EHA highlighted outcomes in patients with active relapsed or refractory acute myeloid leukemia (r/r AML) enrolled in the SIERRA trial who had a TP53 mutation and long-term efficacy results in this older patient population.
Iomab-B led bone marrow transplant improved survival in patients with high-risk relapsed or refractory acute myeloid leukemia including those with a TP53 mutation Iomab-B safely delivered radiation to the target bone marrow at greater amounts than achievable with total body irradiation while sparing healthy non-target organs and enabled 100% access to bone marrow transplant Novel linker technology supports Actinium's Antibody Radiation Conjugate pipeline expansion in solid tumor indications NEW YORK , June 10, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today highlighted data from multiple abstracts that were presented at the 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting being held June 8 – 11, 2024, in Toronto, Canada. The presentations featured results from the Phase 3 SIERRA trial of Iomab-B, a CD45 targeting ARC with the Iodine-131 payload, intended for conditioning to prepare patients with active relapsed or refractory acute myeloid leukemia (r/r AML) for a potentially curative bone marrow transplant (BMT).
Actinium Pharmaceuticals is a biopharmaceutical company in the late stages of development that is dedicated to creating radiotherapies for patients with AML. Their main product, Iomab-B, has demonstrated positive outcomes in trials by improving survival rates for older patients and attacking leukemia-specific antigens. Through partnerships like the one with Immedica AB for the EUMENA market, Actinium aims to enhance its global market position.
Given the volatility of the medical therapeutic sector, it makes sense to think about investing in biotech stocks priced under $10. For instance, if you bought shares in a well-known, expensive company, only to see the stock plummet due to a disappointing clinical outcome.
Actinium Pharmaceuticals continues to make progress with their radiolabelled CD45 antibody Iomab-B, which has potential beyond market expectations. The main pipeline update is the presentation of findings in patients with TP53 mutation, showing improved overall survival with Iomab-B. Actinium Pharmaceuticals has a relatively stable position with $83 million in cash and 6 more quarters of cash on hand, but may need to tie a BLA submission with a public offering.
Actinium is making radiolabeled antibodies for use in hematologic cancers. Previously reported phase 3 trial results give a strong indicator of success at the regulatory level. No respect from the market means Actinium could be in a good position for upward movement.
What type of business is Actinium Pharmaceuticals?
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
What sector is Actinium Pharmaceuticals in?
Actinium Pharmaceuticals is in the Healthcare sector
What industry is Actinium Pharmaceuticals in?
Actinium Pharmaceuticals is in the Biotechnology industry
What country is Actinium Pharmaceuticals from?
Actinium Pharmaceuticals is headquartered in United States
When did Actinium Pharmaceuticals go public?
Actinium Pharmaceuticals initial public offering (IPO) was on 27 December 2012
What is Actinium Pharmaceuticals website?
https://www.actiniumpharma.com
Is Actinium Pharmaceuticals in the S&P 500?
No, Actinium Pharmaceuticals is not included in the S&P 500 index
Is Actinium Pharmaceuticals in the NASDAQ 100?
No, Actinium Pharmaceuticals is not included in the NASDAQ 100 index
Is Actinium Pharmaceuticals in the Dow Jones?
No, Actinium Pharmaceuticals is not included in the Dow Jones index
When does Actinium Pharmaceuticals report earnings?
The next expected earnings date for Actinium Pharmaceuticals is 14 August 2024